F.D.A. Commissioner Marty Makary Resigns After Weeks of Pressure
Christina Jewett / nytimes - The agency’s top food official will step in as acting commissioner, after Dr. Makary’s tumultuous run as the nation’s top food, drug, tobacco and medical device regulator.
AI Summary: F.D.A. commissioner Marty Makary resigned after weeks of intense scrutiny and internal pressure over leadership and policy choices, following reports he faced possible removal. The agency now confronts leadership turbulence as officials rush to steady regulatory priorities, reassure stakeholders and clean up an exit that leaves unfinished reviews and awkward staff memos.
- Firing reports and buildup to Makary's ouster (4)
- Regulatory ripple effects and agency departures (3)
- Resignation announced and immediate leadership vacuum (5)
- All Other Stories
Firing reports and buildup to Makary's ouster
Regulatory ripple effects and agency departures
Resignation announced and immediate leadership vacuum
All Other Stories
Blog Post
FDA Commissioner Marty Makary has resigned after weeks of intense scrutiny and internal pressure, multiple outlets reported.
The resignation follows reports that President Trump had approved a plan to oust Makary — a report the White House publicly downplayed — and contemporaneous reporting that Makary was preparing to step down. Makary was confirmed as FDA commissioner in March 2025. The New York Times said the agency’s top food official will serve as acting commissioner.
Observers describe Makary’s tenure as tumultuous, marked by leadership upheaval, mass layoffs, political pressure and public disputes with drugmakers. Agency officials are scrambling to steady regulatory priorities, reassure stakeholders and manage an exit that leaves unfinished reviews and awkward staff memos.